BGMD - BG Medicine, Inc.

0.0001
0.000   100.000%

Share volume: 11,820
Last Updated: 04-21-2025
Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances: 0.03%

PREVIOUS CLOSE
CHG
CHG%
$0.00
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
8%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 20%
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$0.00
P/E Ratio 
N/A
DAY RANGE
$0.00 - $0.00
EPS 
N/A
52 WEEK RANGE
$0.00 - $0.00
52 WEEK CHANGE
N/A
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$11,820
AVERAGE 30 VOLUME 
$4,278
Company detail
CEO: Paul R. Sohmer
Region: US
Website: www.bg-medicine.com
Employees: 5
IPO year: 2015
Issue type:
Market: OTCM
Industry: Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances
Sector: Manufacturing

BG Medicine, Inc. engages in the research and development, clinical research, manufacture and sale of diagnostic products for heart failure and related disorders. It distributes its products such as BGM Galectin-3 to clinical laboratories, hospitals and health care provider. The company was founded in February 2000 and is headquartered in Waltham, MA.

Recent news
No news available